Literature DB >> 25685642

Facial nerve function after the extended translabyrinthine approach.

Mia E Miller1, Bill Mastrodimos2, Roberto A Cueva3.   

Abstract

Objective To evaluate facial nerve function after excision of petroclival/anterior cerebellopontine angle (CPA) meningiomas by the extended translabyrinthine (EXTL) approach and compare these with outcomes after the transcochlear and transotic approaches. Design Retrospective chart review. Setting/Participants A search of archived surgical cases at a single institution between January 1, 1995, and January 1, 2012. Main Outcome Measures Facial function measured on the House-Brackmann (HB) scale. Results A total of 16 patients underwent the EXTL approach for primary excision of petroclival meningiomas. Average tumor size was 4.6 cm, and six patients had gross total resection. Average length of follow-up was 36.4 months. Two patients required reoperation for tumor regrowth. Preoperative facial function was HB I or II in all patients with available examinations. Immediate postoperative facial nerve function ranged from HB I to HB VI. In patients with an intact facial nerve at surgery, all but one had long-term facial function of HB I or II. A robust response on intraoperative facial nerve monitoring was prognostic of favorable long-term facial function. Facial function declined in some patients after postoperative radiation or revision surgery. Conclusions The EXTL approach allows excellent exposure of petroclival/anterior CPA lesions and should be favored to improve facial outcomes.

Entities:  

Keywords:  cerebellopontine angle; facial paralysis; meningioma; petroclival junction

Year:  2014        PMID: 25685642      PMCID: PMC4318740          DOI: 10.1055/s-0034-1368146

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  16 in total

1.  The transcochlear approach to the skull base.

Authors:  W F House; W E Hitselberger
Journal:  Arch Otolaryngol       Date:  1976-06

2.  Petroclival meningiomas: study on outcomes, complications and recurrence rates.

Authors:  Anil Nanda; Vijayakumar Javalkar; Anirban Deep Banerjee
Journal:  J Neurosurg       Date:  2010-12-24       Impact factor: 5.115

3.  Infratemporal fossa approach to lesions in the temporal bone and base of the skull.

Authors:  U Fisch; H C Pillsbury
Journal:  Arch Otolaryngol       Date:  1979-02

4.  Transcochlear approach to lesions of the cerebellopontine angle and clivus.

Authors:  A De la Cruz
Journal:  Rev Laryngol Otol Rhinol (Bord)       Date:  1981 Jan-Feb

Review 5.  Facial nerve outcomes after surgery for large vestibular schwannomas: do surgical approach and extent of resection matter?

Authors:  Richard K Gurgel; Salim Dogru; Richard L Amdur; Ashkan Monfared
Journal:  Neurosurg Focus       Date:  2012-09       Impact factor: 4.047

6.  The transcochlear approach revisited.

Authors:  S I Angeli; A De la Cruz; W Hitselberger
Journal:  Otol Neurotol       Date:  2001-09       Impact factor: 2.311

7.  Combined petrosal approaches in the management of temporal bone meningiomas.

Authors:  Andrew Baugh; Todd A Hillman; Clough Shelton
Journal:  Otol Neurotol       Date:  2007-02       Impact factor: 2.311

8.  Evolution of surgical approaches in the treatment of petroclival meningiomas: a retrospective review.

Authors:  Nicholas C Bambakidis; U Kumar Kakarla; Louis J Kim; Peter Nakaji; Randall W Porter; C Phillip Daspit; Robert F Spetzler
Journal:  Neurosurgery       Date:  2007-11       Impact factor: 4.654

9.  Transzygomatic extended middle fossa approach for upper petroclival skull base lesions.

Authors:  Jin-cheng Zhao; James K Liu
Journal:  Neurosurg Focus       Date:  2008       Impact factor: 4.047

10.  Experience with 36 surgical cases of petroclival meningiomas.

Authors:  M Samii; M Tatagiba
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

View more
  1 in total

1.  Intradural Transpetrosectomy for Petrous Apex Meningiomas.

Authors:  Shuo Han; Xiao-Hua Zhang; Dong-Hua Han; Yi-Chao Jin
Journal:  J Korean Neurosurg Soc       Date:  2019-08-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.